Skip to main content
Premium Trial:

Request an Annual Quote

Axys Creates Subsidiary To Market Combi Chem

Premium

SOUTH SAN FRANCISCO--Axys Pharmaceuticals, announced this month that is has formed a new wholly owned subsidiary called Axys Advanced Technologies. The new company, formerly the advanced technologies division of Axys, has been created to market Axys's combinatorial chemistry techniques. Axys Advanced Technologies produces and sells diversity libraries for general screening and directed libraries focused on specific protein targets. It also offers technology and follow-on medicinal chemistry services. Current customers for the new unit include Parke-Davis, Rhone-Poulenc Rorer, Pharmacia & Upjohn, Signal Pharmaceuticals, Protein Design Labs, and Daiichi Pharmaceutical of Japan.

Filed under

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.